TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01354093
Drug: zeaxanthin
Normalized name: Zeaxanthin
DrugBank: Zeaxanthin (DB11176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of EyePromise 10 (zeaxanthin) supplement, taken twice a day
Study: NCT01354093
Drug: zeaxanthin
Normalized name: Zeaxanthin
DrugBank: Zeaxanthin (DB11176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of EyePromise 10 (zeaxanthin) supplement, taken once a day
Study: NCT00314613
Drug: Antipsychotic/Risperidone Consta
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02882347
Drug: Somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02724202
Drug: Curcumin
Normalized name: Curcumin
DrugBank: Curcumin (DB11672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin is supplied as soft-gel capsule. It is a micronized rhizome extract containing phospholipids and 500mg of pure curcuminoids (95% curcumin, 5% desmethoxycurcumin) suspended in turmeric essential oil.
Study: NCT01657981
Drug: YM150
Normalized name: Yohimbine
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14C-labeled YM150, oral solution
Study: NCT00861887
Drug: Standard Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin treatment 125 mg po every 6 hours x 2 weeks
Study: NCT00861887
Drug: Extended Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin 125 mg every 6 hours x 2 weeks
Study: NCT03262961
Drug: Sildenafil 20 MG
Normalized name: sildenafil 20 MG
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01246960
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT01246960
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT02550145
Drug: Exendin (9-39)
Normalized name: EXENDIN (9-39)
DrugBank: Avexitide (DB14806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of Exendin (9-39) during standardized oral glucose tolerance test (OGTT).
Study: NCT00980044
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Medication
Study: NCT01409096
Drug: Pregnenolone
Normalized name: Pregnenolone
DrugBank: Pregnenolone (DB02789)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and central nervous system.
Study: NCT02172729
Drug: Adductor canal block with 20 ml lidocaine, single bolus
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duration of an adductor canal block with 20 ml lidocaine, single bolus, administered as 5 or 15 mg/ml
Study: NCT04518501
Drug: Arsenic trioxide Tablet +Fuzuloparib Capsules
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arsenic trioxide Tablet : 0.27\*9 tid po consecutive 21 days with 1 week rest． Fuzuloparib Capsules: 150 mg bid po
Study: NCT03440385
Drug: Ozanimod
Normalized name: Ozanimod
DrugBank: Ozanimod (DB12612)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT02301897
Drug: Telapristone Acetate
Normalized name: Telapristone acetate
DrugBank: Telapristone acetate (DB05253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telapristone acetate, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
Study: NCT02965781
Drug: SADBE
Normalized name: LEMON 5 g in 50 g / VIOLA ODORATA FLOWER 10 g in 50 g / TOCOPHEROL 5 g in 50 g TOPICAL CREAM [XIMONTH Violette Beruhigende Hauttherapie Salbe]
DrugBank: Lemon (DB10538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical solution
Study: NCT02675400
Drug: Vyvanse
Normalized name: Vyvanse
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Half of the participants (fathers) will be randomized to receive Vyvanse.
Study: NCT02675400
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If Vyvanse is not well tolerated, methylphenidate can be prescribed.
Study: NCT02179034
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive no nicotine, low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
Study: NCT02538614
Drug: Idelalisib
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets administered orally twice daily
Study: NCT02538614
Drug: BI 836826
Normalized name: BI 836826
DrugBank: BI-836826 (DB17322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration as a rate-controlled infusion
Study: NCT01605994
Drug: BMS-933043
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01347814
Drug: Domperidone 10mg
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg domperidone tablet 30 minutes before a test-meal.
Study: NCT00314977
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel: (arm A: 100 mg/m2) and (arm B: 75 mg/m2)
Study: NCT03474276
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of Albendazole at inclusion of the child : 200mgs, one administration
Study: NCT00000600
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000600
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02288130
Drug: GnRHa
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02288130
Drug: Ulipristal
Normalized name: Ulipristal
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03116126
Drug: Guanfacine
Normalized name: Guanfacine
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2mg oral daily tablet
Study: NCT03251508
Drug: Peanut OIT
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given increasing doses of the peanut flour as peanut oral immunotherapy (OIT) with increasing doses every 2 weeks over a period of 3 months up to a 300 mg target dose. This 300 mg peanut OIT maintenance dose is then continued daily for 3 months. Participants will then introduce dietary peanut of approximately 300 mg of peanut protein and continue daily ingestion for an additional 6 months.
Study: NCT00064857
Drug: Pycnogenol
Normalized name: Pycnogenol
DrugBank: Maritime pine extract (DB15786)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02940548
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 30\~60mg/day for 8 weeks
Study: NCT02940548
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate 5\~10mg/day for 8 weeks
Study: NCT02328495
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
Study: NCT00004128
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004128
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004128
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004128
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03639935
Drug: Rucaparib
Normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rucaparib 600 mg PO BID days 1-28
Study: NCT03639935
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 240 mg IV days 1 and 15
Study: NCT04507204
Drug: Adhansia XR
Normalized name: Adhansia XR
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate extended-release capsules taken once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, and 85 mg)
Study: NCT04507204
Drug: Concerta
Normalized name: Concerta
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An osmotic-controlled oral release delivery system (OROS) of methylphenidate HCl (MPH) extended-release tablets taken once daily (18 mg, 27 mg, 36 mg, and 54 mg)
Study: NCT04997850
Drug: lenvatinib + sindilimab/carrelizumab
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next treatment cycle was carried out. The trial was terminated if the drug was stopped for more than 28 days due to adverse drug reactions or other reasons. Patients with PD after 6 cycles of sindilimab/carrelizumab treatment were terminated. The follow-up treatment was based on the principle of individualization, multidisciplinary discussion and patients' willingness.
Study: NCT01702298
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will continue pre-study dose of metformin tablet(s) \>=1000 per day
Study: NCT04217265
Drug: Letrozole then misoprostol
Normalized name: Letrozole
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: total dose 5 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
Study: NCT04217265
Drug: placebo then misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo tablets for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
Study: NCT02522767
Drug: Mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02633371
Drug: Oxybutynin 3% gel
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01255774
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: An open-label, study of intravitreally administered ranibizumab
Study: NCT05530057
Drug: Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar)
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle and SB3 8 mg/kg I.V. over 90 minutes on day 1 of cycle 1 . Thereafter, SB3 6 mg/kg will be infused over 30 minutes on day 1 of each subsequent 21-day cycle until progression or unacceptable toxicity.~* Dose reductions for eribulin, but not for SB3, is permitted.~* Two dose reductions (1.1, 0.7 mg/m2) are allowed for eribulin before consideration of study treatment discontinuation. Eribulin could be continued as monotherapy if trastuzumab-similar was discontinued, and vice-versa.
Study: NCT05530057
Drug: Eribulin Mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle until progression or unacceptable toxicity.~* Two dose reductions (1.1, 0.7 mg/m2) are allowed before consideration of study treatment discontinuation.
Study: NCT00624052
Drug: fixed-dose combination of telmisartan 40mg+amlodipine 10mg
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00624052
Drug: fixed-dose combination of telmisartan 80mg+amlodipine10mg
Normalized name: telmisartan 80 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02576288
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: anti-inflammatory properties
Study: NCT02494596
Drug: RhuMab 2C4
Normalized name: rhuMAb 2H7
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 1050 mg via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
Study: NCT01186757
Drug: PF-03715455
Normalized name: PF-03715455
DrugBank: PF-03715455 (DB12138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-03715455 1.6 mg BID
Study: NCT01186757
Drug: PF-03715455
Normalized name: PF-03715455
DrugBank: PF-03715455 (DB12138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-03715455 4mg BID
Study: NCT01186757
Drug: PF-03715455
Normalized name: PF-03715455
DrugBank: PF-03715455 (DB12138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-03715455 10 mg BID
Study: NCT01785030
Drug: 50% Nitrous oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04587492
Drug: Nusinersen
Normalized name: Nusinersen
DrugBank: Nusinersen (DB13161)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with nusinersen
Study: NCT04183686
Drug: ACT-1014-6470 (SAD)
Normalized name: ACT-541468
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ACT-1014-6470; soft capsules for oral use.
Study: NCT02538302
Drug: Minirin
Normalized name: Minirin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Minirin 5 to 10 mg daily for 6 months
Study: NCT02538302
Drug: Oxybutynin
Normalized name: Oxybutynin
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxybutynin 5 to 10 mg daily for 6 months
Study: NCT04183686
Drug: ACT-1014-6470 (MAD)
Normalized name: ACT-541468
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of ACT-1014-6470; soft capsules for oral use.
Study: NCT04183686
Drug: 14C-ACT-1014-6470 microtracer
Normalized name: ACT-541468
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 14C-ACT-1014-6470 microtracer; soft capsules for oral use.
Study: NCT04183686
Drug: 14C-ACT-1014-6470 microtracer placebo
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of matching placebo; soft capsules for oral use.
Study: NCT03322566
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab administered intravenously every 3 weeks.
Study: NCT03322566
Drug: Epacadostat
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epacadostat administered orally twice daily.
Study: NCT03322566
Drug: Platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator selected one of the following regimens: pemetrexed + cisplatin, pemetrexed + carboplatin, or paclitaxel + carboplatin, depending on histology.
Study: NCT03202394
Drug: BIO-11006
Normalized name: BIO-11006
DrugBank: BIO-11006 (DB14886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer.
Study: NCT01438918
Drug: SD-6010
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tablets once a day for 2 years
Study: NCT00560417
Drug: Insulin Lispro Protamine Suspension
Normalized name: Insulin Lispro Protamine Suspension and Insulin Lispro Injection
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered subcutaneously once a day at bedtime
Study: NCT00560417
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered subcutaneously once a day at bedtime
Study: NCT00070304
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV over 100 minutes dose 1000 mg/m2/dose in 500 ml NS on days 1 and 8
Study: NCT00070304
Drug: vinorelbine tartrate
Normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV over 6-10 minutes (central venous catheter). Dose 25 mg/m2/dose on days 1 and 8
Study: NCT02736071
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Women will receive oral Tramadol 100mg 2 hours before the procedure
Study: NCT03781063
Drug: Lasofoxifene
Normalized name: lasofoxifene
DrugBank: Lasofoxifene (DB06202)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Estrogen receptor antagonist antineoplastic agent
Study: NCT03781063
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Estrogen receptor antagonist antineoplastic agent
Study: NCT00095550
Drug: Irbesartan/HCTZ
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, Irbesartan 150 mg/HCTZ 12.5 mg, Once daily, 12 weeks.
Study: NCT00095550
Drug: Irbesartan monotherapy
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 150 mg, Once daily, 12 weeks.
Study: NCT00095550
Drug: HCTZ monotherapy
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 12.5 mg, Once daily, 12 weeks.
Study: NCT04600284
Drug: AD-2101
Normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AD-2101 16/5mg
Study: NCT04600284
Drug: AD-2102
Normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AD-2102 25mg
Study: NCT04600284
Drug: AD-2101 + AD-2102
Normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AD-2101 16/5mg + AD-2102 25mg
Study: NCT00553254
Drug: PF-00299804
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single arm (no comparator) study, oral once daily dosing, dose escalation (it is a phase 1/2 study) until disease progression, unacceptable toxicity or withdrawal of consent
Study: NCT00398814
Drug: Perifosine
Normalized name: Perifosine
DrugBank: Perifosine (DB06641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.
Study: NCT00398814
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.
Study: NCT02448381
Drug: SGX301 (synthetic hypericin)
Normalized name: Hypéricine
DrugBank: Hypericin (DB13014)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% SGX301 in USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.
Study: NCT02640300
Drug: Clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Switching to clozapine with immediate or gradual antipsychotic discontinuation
Study: NCT05480007
Drug: sitagliptin and metformin
Normalized name: Sitagliptin and Metformin Hydrochloride Extended Release Tablets
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sitagliptin plus metformin group who received sitagliptin (100mg per day) and metformin (500 mg three times per day) (20 patients)
Study: NCT05480007
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sitagliptin treatment (100mg per day)
Study: NCT05480007
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin group who received metformin (500mg three times per day)
Study: NCT01438918
Drug: SD-6010
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tablets once a day for 2 years
Study: NCT03056391
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: \>50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.~\<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine.
Study: NCT02011347
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04308837
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 mg/m2 given by intravenous infusion on days 1, 8, 15, 22 and 29.
Study: NCT02947048
Drug: L1-79
Normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00216190
Drug: Dexmedetomidine HCL Injection
Normalized name: dexmedetomidine hydrochloride Injectable Solution
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00216190
Drug: Midazolam Injection
Normalized name: midazolam Injection
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03895372
Drug: PF-06826647 or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Delivered orally (tablet) once daily (QD) for 16 weeks during the Investigational Treatment Period